Similar articles

• The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.

  Glaser R, Glick HA, Herrmann HC, Kimmel SE. Glaser R, et al. J Am Coll Cardiol. 2006 Feb 7;47(3):529-37. doi: 10.1016/j.jacc.2005.08.070. Epub 2006 Jan 18. J Am Coll Cardiol. 2006. PMID: 16458131
• Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.

  Cannon CP. Cannon CP. Clin Cardiol. 1999 Aug;22(8 Suppl):IV30-6. doi: 10.1002/clc.4960221606. Clin Cardiol. 1999. PMID: 10492851 Free PMC article. Review.
• Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?

  Cole JH, Weintraub WS. Cole JH, et al. Circulation. 2003 Dec 9;108(23):2831-3. doi: 10.1161/01.CIR.0000106681.88891.F2. Circulation. 2003. PMID: 14662689 No abstract available.
• GP IIb/IIIa inhibitors: an evidence-based approach to their use.

  [No authors listed] [No authors listed] Med Manag Netw. 1999 Mar;7(3):5-9. Med Manag Netw. 1999. PMID: 10346546 No abstract available.
• Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.

  Roe MT, Moliterno DJ. Roe MT, et al. J Thromb Thrombolysis. 1999 Jun;7(3):247-57. doi: 10.1023/a:1008927025962. J Thromb Thrombolysis. 1999. PMID: 10373718 Review. No abstract available.